SciVision Biotech Future Growth

Future criteria checks 2/6

SciVision Biotech is forecast to grow revenue at 34% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth	19.0%
Revenue growth rate	34.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	18 Jun 2024

Recent future growth updates

No updates

Recent updates

SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50

Jun 28

SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

Jun 14

SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly

Jun 04

Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio

Apr 01

Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Apr 20

SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital

Apr 02

Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?

Mar 15

Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Feb 25

Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?

Feb 05

Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Jan 18

Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?

Jan 01

SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years

Dec 14

Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Nov 25

Earnings and Revenue Growth Forecasts

TWSE:1786 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	1,431	N/A	N/A	555	1
12/31/2024	1,036	N/A	N/A	494	1
3/31/2024	788	197	291	305	N/A
12/31/2023	713	178	257	272	N/A
9/30/2023	670	168	202	223	N/A
6/30/2023	628	159	188	209	N/A
3/31/2023	577	148	151	169	N/A
12/31/2022	557	142	167	182	N/A
9/30/2022	538	138	151	162	N/A
6/30/2022	500	112	84	97	N/A
3/31/2022	495	104	116	129	N/A
12/31/2021	506	102	73	99	N/A
9/30/2021	497	112	98	159	N/A
6/30/2021	491	126	65	129	N/A
3/31/2021	468	116	58	127	N/A
12/31/2020	467	128	60	126	N/A
9/30/2020	465	133	83	122	N/A
6/30/2020	447	124	85	189	N/A
3/31/2020	443	127	30	171	N/A
12/31/2019	438	121	2	204	N/A
9/30/2019	410	112	-109	140	N/A
6/30/2019	380	103	-76	120	N/A
3/31/2019	330	81	-60	99	N/A
12/31/2018	330	87	16	112	N/A
9/30/2018	314	73	-8	111	N/A
6/30/2018	296	58	-49	101	N/A
3/31/2018	314	55	-46	109	N/A
12/31/2017	258	17	N/A	16	N/A
9/30/2017	244	21	N/A	26	N/A
6/30/2017	251	-28	N/A	-19	N/A
3/31/2017	231	-28	N/A	-50	N/A
12/31/2016	228	-26	N/A	38	N/A
9/30/2016	218	-37	N/A	37	N/A
6/30/2016	238	36	N/A	95	N/A
3/31/2016	250	41	N/A	107	N/A
12/31/2015	265	55	N/A	50	N/A
9/30/2015	237	22	N/A	33	N/A
6/30/2015	197	-5	N/A	11	N/A
3/31/2015	181	-9	N/A	17	N/A
12/31/2014	158	-22	N/A	2	N/A
9/30/2014	175	6	N/A	19	N/A
6/30/2014	188	26	N/A	2	N/A
3/31/2014	194	34	N/A	15	N/A
12/31/2013	201	40	N/A	37	N/A
9/30/2013	226	63	N/A	50	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1786's forecast earnings growth is above the savings rate (1%).

Earnings vs Market: Insufficient data to determine if 1786's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 1786's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 1786's revenue (34% per year) is forecast to grow faster than the TW market (11.8% per year).

High Growth Revenue: 1786's revenue (34% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1786's Return on Equity is forecast to be high in 3 years time

SciVision Biotech Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50

Dividend of NT$2.50 announced

SciVision Biotech Inc Approves Cash Dividend, Payable on August 16, 2024

SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

New minor risk - Share price stability

SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly

Investor sentiment improves as stock rises 18%

Scivision Biotech Inc.'s Product, One-Injection Typehyaluronic Acid Synovial Fluid Supplement"Hyajoint Plus"Has Obtained Medical Device License

SciVision Biotech Inc. to Report Q1, 2024 Results on May 09, 2024

SciVision Biotech Inc. to Report Q1, 2024 Results on May 09, 2024

Investor sentiment improves as stock rises 21%

Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio

SciVision Biotech Inc., Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released: EPS: NT$2.66 (vs NT$2.14 in FY 2022)

New minor risk - Shareholder dilution

New minor risk - Earnings quality

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: NT$0.77 (vs NT$0.60 in 2Q 2022)

SciVision Biotech Inc. Announces Corporate Governance Officer Changes

Upcoming dividend of NT$1.98 per share at 2.1% yield

New minor risk - Dividend sustainability

Investor sentiment improves as stock rises 17%

SciVision Biotech Inc. Approves Cash Dividend, Payable on August 18, 2023

New minor risk - Share price stability

SciVision Biotech Inc. Approves Cash Dividend, Payable on August 18, 2023

Full year 2022 earnings released: EPS: NT$2.14 (vs NT$1.54 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$0.69 (vs NT$0.30 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: NT$0.60 (vs NT$0.48 in 2Q 2021)

Upcoming dividend of NT$1.42 per share

SciVision Biotech Inc. Announces Cash Dividend, Payable on August 18, 2022

SciVision Biotech Inc. Announces Hyaluronic Acid Flexotron Forte (1%) Has Obtained Medical Device License

SciVision Biotech Inc. Announces Executive Changes

First quarter 2022 earnings released: EPS: NT$0.41 (vs NT$0.37 in 1Q 2021)

Less than half of directors are independent

Third quarter 2021 earnings released: EPS NT$0.30 (vs NT$0.51 in 3Q 2020)

Upcoming dividend of NT$0.96 per share

Second quarter 2021 earnings released: EPS NT$0.52 (vs NT$0.37 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$0.40 (vs NT$0.59 in 1Q 2020)

Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital

Full year 2020 earnings released: EPS NT$2.10 (vs NT$1.99 in FY 2019)

Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?

Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?

Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

New 90-day low: NT$60.00

Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?

SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years

New 90-day low: NT$63.60

Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Third quarter 2020 earnings released: EPS NT$0.56

New 90-day high: NT$73.30

New 90-day high - NT$67.00

First half earnings released

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies